Gen­fit goes to Chi­na with a deal worth up to $228M for NASH drug

6 years ago
Deals
China

Alex­ion wins pri­or­i­ty re­view for Ul­tomiris' aHUS in­di­ca­tion; FDA ex­pands ap­proval of Ver­tex's Symdeko

6 years ago
News Briefing

Bet­ter than Am­bi­en? Min­er­va soars on PhI­Ib up­date on sel­torex­ant for in­som­nia

6 years ago
R&D

Gene ther­a­py biotech sees its stock rock­et high­er on promis­ing re­sults for rare cas­es of but­ter­fly dis­ease

6 years ago
R&D
Cell/Gene Tx

Ab­b­Vie gets a green light to re­sume re­cruit­ing pa­tients for one myelo­ma study — but Ven­clex­ta re­mains un­der a cloud

6 years ago
R&D
FDA+

In sur­prise switch, Bris­tol-My­ers is sell­ing off block­buster Ote­zla, promis­ing to com­plete Cel­gene ac­qui­si­tion — ...

6 years ago
Deals

Bris­tol-My­ers star Op­di­vo fails sur­vival test in a matchup with Nex­avar aimed at shak­ing up the big HCC mar­ket

6 years ago
R&D
Pharma

In $86M IPO pitch, Mirum spells out plans to turn Shire dis­cards in­to or­phan liv­er drug suc­cess­es

6 years ago
Financing

FDA spurns hay fever drug from In­di­a's Glen­mark

6 years ago
Pharma
FDA+

Ox­ford, Evotec ramp up LAB10x with AI ex­perts at Sen­syne — fo­cused on biotech spin­outs

6 years ago
Startups
AI

Why would the FDA ap­prove an­oth­er con­tro­ver­sial drug to spur a woman’s li­bido with these da­ta? And why no ex­pert ...

6 years ago
Bioregnum
Pharma

Fol­low­ing news of job cuts in Eu­ro­pean R&D ops, Sanofi con­firms it’s of­fer­ing US work­ers an 'ear­ly ex­it'

6 years ago
People
R&D

ICER goes af­ter No­var­tis for over­pric­ing MS drug; Val­ne­va, Glax­o­SmithK­line breaks vac­cine pact

6 years ago
News Briefing

Maze in­ter­im chief Charles Hom­cy pass­es ba­ton to Ja­son Colo­ma; William Col­lier tapped as CEO of Ar­bu­tus

6 years ago
Peer Review

Re­gen­eron/Sanofi's an­ti­body un­der­whelms in asth­ma study — shares of ri­val Anap­tys­Bio pay the price

6 years ago
R&D

Green-light­ed in Japan, FDA quick­ly spurns Dai­ichi Sanky­o's flawed ap­pli­ca­tion for AML drug

6 years ago
R&D

J&J's Es­ke­t­a­mine, at cur­rent price, is 'low val­ue for mon­ey' — ICER

6 years ago
Pharma

Which top 10 big phar­mas have the most to gain — or lose — over the next 5 years?

6 years ago
Pharma

HIV, pneu­mo­coc­cal — and what? Mer­ck­'s un­ex­pect­ed pipeline high­light ex­cites a lit­tle biotech

6 years ago
R&D

Af­ter years of claims and ac­cu­sa­tions, fraud­ster Mar­tin Shkre­li set­tles up with Retrophin

6 years ago
People

Roche/Ex­elix­is' Cotel­lic fiz­zles in piv­otal melanoma study

6 years ago
R&D

NE­JM ap­points Er­ic Ru­bin to suc­ceed Jef­frey Drazen as EIC; Am­phastar pre­vails against Mo­men­ta/San­doz in years-long ...

6 years ago
News Briefing

'Our lega­cy mat­ter­s': Mer­ck maps out Keytru­da king­dom while spot­light­ing ad­vances in vac­cines, hos­pi­tal care

6 years ago
R&D
Pharma

Eli Cas­din backs Codex­is' plat­form tech with $50M eq­ui­ty buy

6 years ago
People
Financing
First page Previous page 924925926927928929930 Next page Last page
A service from the Financial Times